JP2006502228A5 - - Google Patents

Download PDF

Info

Publication number
JP2006502228A5
JP2006502228A5 JP2004543559A JP2004543559A JP2006502228A5 JP 2006502228 A5 JP2006502228 A5 JP 2006502228A5 JP 2004543559 A JP2004543559 A JP 2004543559A JP 2004543559 A JP2004543559 A JP 2004543559A JP 2006502228 A5 JP2006502228 A5 JP 2006502228A5
Authority
JP
Japan
Prior art keywords
vaccine composition
hiv
composition according
plg
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004543559A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502228A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/031935 external-priority patent/WO2004032860A2/en
Publication of JP2006502228A publication Critical patent/JP2006502228A/ja
Publication of JP2006502228A5 publication Critical patent/JP2006502228A5/ja
Pending legal-status Critical Current

Links

JP2004543559A 2002-10-07 2003-10-07 Ｈｉｖワクチン処方物 Pending JP2006502228A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41657302P 2002-10-07 2002-10-07
PCT/US2003/031935 WO2004032860A2 (en) 2002-10-07 2003-10-07 Hiv vaccine formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011226126A Division JP2012012416A (ja) 2002-10-07 2011-10-13 Ｈｉｖワクチン処方物

Publications (2)

Publication Number Publication Date
JP2006502228A JP2006502228A (ja) 2006-01-19
JP2006502228A5 true JP2006502228A5 (https=) 2006-11-24

Family

ID=32093869

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004543559A Pending JP2006502228A (ja) 2002-10-07 2003-10-07 Ｈｉｖワクチン処方物
JP2011226126A Pending JP2012012416A (ja) 2002-10-07 2011-10-13 Ｈｉｖワクチン処方物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011226126A Pending JP2012012416A (ja) 2002-10-07 2011-10-13 Ｈｉｖワクチン処方物

Country Status (7)

Country Link
US (3) US20060110736A1 (https=)
EP (1) EP1565583A4 (https=)
JP (2) JP2006502228A (https=)
AU (1) AU2003282498A1 (https=)
CA (2) CA2501476A1 (https=)
WO (1) WO2004032860A2 (https=)
ZA (1) ZA200503554B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005067966A1 (en) * 2004-01-07 2005-07-28 Biomedical Research Models, Inc. Methods for tailoring the immune response to an antigen or immunogen
US8399423B2 (en) * 2005-10-12 2013-03-19 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
EP1913881B1 (en) 2006-10-17 2014-06-11 Covidien LP Apparatus for applying surgical clips
WO2008076554A2 (en) * 2006-11-13 2008-06-26 Georgia Tech Research Corporation Methods for modifying virus surfaces
BR122016015627A2 (pt) * 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
US20110208212A1 (en) * 2010-02-19 2011-08-25 Zergiebel Earl M Surgical clip applier
US9358015B2 (en) 2008-08-29 2016-06-07 Covidien Lp Endoscopic surgical clip applier with wedge plate
US8403945B2 (en) 2010-02-25 2013-03-26 Covidien Lp Articulating endoscopic surgical clip applier
WO2012040101A1 (en) 2010-09-21 2012-03-29 University Of Miami Compositions and methods for inducing migration by dendritic cells and an immune response
WO2012040266A2 (en) * 2010-09-24 2012-03-29 University Of Miami Gene-based adjuvants and compositions thereof to increase antibody production in response to gene-based vaccines
US9011464B2 (en) 2010-11-02 2015-04-21 Covidien Lp Self-centering clip and jaw
US9186153B2 (en) 2011-01-31 2015-11-17 Covidien Lp Locking cam driver and jaw assembly for clip applier
US9532787B2 (en) 2012-05-31 2017-01-03 Covidien Lp Endoscopic clip applier
WO2014107731A1 (en) 2013-01-07 2014-07-10 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
CN110121336A (zh) 2017-01-05 2019-08-13 弗莱德哈钦森癌症研究中心 改善疫苗功效的系统和方法
KR20250099256A (ko) 2018-01-18 2025-07-01 프레드 허친슨 캔서 센터 세포 활성화 상태를 조절함으로써 생체내 면역 세포의 염증 상태의 변경

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5100792A (en) 1984-11-13 1992-03-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US4663161A (en) 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
US4871488A (en) 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
CA2017507C (en) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant formulation comprising a submicron oil droplet emulsion
US5603960A (en) * 1993-05-25 1997-02-18 O'hagan; Derek T. Preparation of microparticles and method of immunization
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6171596B1 (en) * 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US20030050263A1 (en) * 1994-07-15 2003-03-13 The University Of Iowa Research Foundation Methods and products for treating HIV infection
US6884435B1 (en) * 1997-01-30 2005-04-26 Chiron Corporation Microparticles with adsorbent surfaces, methods of making same, and uses thereof
ATE235890T1 (de) * 1997-01-30 2003-04-15 Chiron Corp Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr
US6099847A (en) * 1997-05-15 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric Gag pseudovirions
WO1999030737A1 (en) * 1997-12-16 1999-06-24 Chiron Corporation Use of microparticles combined with submicron oil-in-water emulsions
US7393630B2 (en) * 1997-12-16 2008-07-01 Novartis Vaccines And Diagnostics, Inc. Use of microparticles combined with submicron oil-in-water emulsions
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
DE69930642T2 (de) 1998-07-29 2006-12-28 Chiron Corp., Emeryville Mikropartikel mit adsorbenten oberflächen, verfahren zu ihrer herstellung und ihrer verwendung
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
JP4776075B2 (ja) 1998-12-31 2011-09-21 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 改変ｈｉｖｅｎｖポリペプチド
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US7935805B1 (en) 1998-12-31 2011-05-03 Novartis Vaccines & Diagnostics, Inc Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
AUPQ520800A0 (en) * 2000-01-21 2000-02-17 Alfred Hospital Prime-boost vaccination strategy
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
MXPA03002643A (es) * 2000-09-28 2003-06-19 Chiron Corp Composiciones de microparticulas y metodos para producirlas.
ES2260291T3 (es) * 2000-09-28 2006-11-01 Chiron Corporation Microparticulas para la administracion de acidos nucleicos heterologos.
US20030199071A1 (en) * 2000-12-08 2003-10-23 Solomon Langermann Mutant proteins, high potency inhibitory antibodies and fimch crystal structure
EP2280074A3 (en) * 2001-07-05 2011-06-22 Novartis Vaccines and Diagnostics, Inc. Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
EP1411770A4 (en) * 2001-07-05 2006-05-10 Chiron Corp POLYNUCLEOTIDES CODING FOR ANTIGENIC C-TYPE HIV POLYPEPTIDES, POLYPEPTIDES AND THEIR USE
US20030170614A1 (en) * 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2458995C (en) * 2001-08-31 2013-04-30 Chiron Corporation Polynucleotides encoding antigenic hiv type b polypeptides, polypeptides and uses thereof
WO2004065578A2 (en) 2003-01-14 2004-08-05 Chiron Corporation Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles
US8974986B2 (en) 2007-07-06 2015-03-10 M. Technique Co., Ltd. Method for producing metal-supported carbon, method for producing crystals consisting of fullerene molecules and fullerene nanowhisker/nanofiber nanotubes, and apparatus for producing the same

Similar Documents

Publication Publication Date Title
Kayraklioglu et al. CpG oligonucleotides as vaccine adjuvants
JP2006502228A5 (https=)
Taslimi et al. Leishmaniasis and various immunotherapeutic approaches
Halperin et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18–55 years of age
Salonius et al. The road to licensure of a DNA vaccine
US20190211065A1 (en) High potency immunogenic compositions
Higgins et al. Immunostimulatory DNA as a vaccine adjuvant
Tomai et al. TLR7/8 agonists as vaccine adjuvants
JP2007523863A5 (https=)
JP2010519205A5 (https=)
Zhang et al. Effects of astragalus polysaccharide on the immune response to foot-and-mouth disease vaccine in mice
RU2006106848A (ru) Улучшения в вакцинации
JP2011026328A (ja) オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
JP2001526688A (ja) オリゴヌクレオチドアジュバント
TW200307557A (en) Stabilized synthetic immunogen delivery systems
JP2006020648A5 (https=)
MX2011012147A (es) Inmunoterapia de vacuna.
CN110612118A (zh) 用于引起针对hbv的免疫应答的病毒样粒子
JP2008000001A (ja) 免疫刺激オリゴヌクレオチドおよびその医薬用途
JP2023506439A (ja) 医薬組成物及びその用途
CN100425287C (zh) 肿瘤疫苗
US8734806B2 (en) Immunogenic composition and use thereof
JP2003530088A5 (https=)
Stephen et al. Swine influenza virus vaccine: potentiation of antibody responses in rhesus monkeys
EP3328424A1 (en) Enhanced immune response in porcine species